Figure 7

Effect of MG132, an inhibitor of NF-κB, on LPS-induced CDX2 and MUC2 expression in cultured BECs from PCK rats. (a) CDX2 and MUC2 mRNA levels of cultured BECs incubated with LPS (10 μg/ml) for 6 h (2nd lane) were reduced in comparison with CDX2 and MUC2 mRNA levels in cultured BECs incubated with LPS (10 μg/ml) for 6 h after treatment with MG132 (1 μM, an inhibitor of NF-κB) for 30 min (3rd lane). No significant expression of CDX2 or MUC2 mRNA was seen in the control (treatment with basic medium alone (1st lane) or on treatment with MG132 (1 μM) alone (4th lane). Gel image of CDX2 and MUC2 mRNA expression. (b) NIH image of the gel image of CDX2 and MUC2 mRNA expression shown in (a). CDX2 mRNA and MUC2 mRNA levels were reduced to 30.2±3.4 and 33.7±0.9% (2nd and 3rd columns), respectively (both, <0.05). Bars indicate mean±s.e.m. No significant expression of CDX2 or MUC2 mRNA was seen in the control (1st column) (treatment with basic medium alone) or on treatment with MG132 (1 μM) alone (4th column). (c) CDX2 and MUC2 protein levels in cultured BECs incubated with LPS (10 μg/ml) for 30 h (middle lane) were markedly decreased when the cells were pretreated with MG132 (1 μmol/l) for 1 h (right lane). The control without LPS treatment is the left lane. Western blotting for CDX2 and MUC2 protein.